BRCA1 and ovarian carcinoma: Approximately 11–15% of ovarian cancer patients have BRCA1/2 germline mutations, 7% have BRCA1/2 somatic mutations, and it has been reported that HRD is found in about 50% of patients with epithelial ovarian cancer [8,9].